Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liquid CAIV-T · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Liquid CAIV-T | DRUG | - |
Inclusion Criteria: * Age 6-59 months of age (not yet reached their 5th birthday) * Parent or guardian available by telephone * Available for illness visits at clinic or at home during the influenza surveillance period * Written informed consent (and Health Insurance Portability and Accountability ...
Liquid CAIV-T is an investigational small molecule being developed for influenza. It is a trivalent, live, cold adapted influenza vaccine studied in children 6 to 59 months of age. The drug is currently in Phase 3 clinical development and remains investigational, not yet approved by regulatory authorities.
Liquid CAIV-T is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical research on this influenza vaccine candidate in the infectious disease therapeutic area.
Liquid CAIV-T is in Phase 3 clinical development for influenza. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in the target patient population.
Liquid CAIV-T has one completed Phase 3 clinical trial registered as NCT00128167. This study, titled 'Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age,' enrolled 8,500 participants across multiple countries including the United States, Belgium, Czechia, Hong Kong, Ireland, South Korea, Taiwan, and the United Kingdom.
Liquid CAIV-T is a formulation of the trivalent, live, cold adapted influenza vaccine, commonly referred to as CAIV-T. The clinical trial NCT00128167 uses both names to describe the investigational vaccine being studied in children aged 6 to 59 months for the prevention of influenza.